Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
| dc.contributor.author | Miles, D. | |
| dc.contributor.author | de haas, S. | |
| dc.contributor.author | Dirix, L. | |
| dc.contributor.author | Romieu, G. | |
| dc.contributor.author | Chan, Arlene | |
| dc.contributor.author | Pivot, X. | |
| dc.contributor.author | Tomczak, P. | |
| dc.contributor.author | Provencher, L. | |
| dc.contributor.author | Cortes, J. | |
| dc.contributor.author | Delmar, P. | |
| dc.contributor.author | Scherer, S. | |
| dc.date.accessioned | 2017-01-30T12:58:04Z | |
| dc.date.available | 2017-01-30T12:58:04Z | |
| dc.date.created | 2014-11-19T01:13:19Z | |
| dc.date.issued | 2013 | |
| dc.identifier.citation | Miles, D. and de haas, S. and Dirix, L. and Romieu, G. and Chan, A. and Pivot, X. and Tomczak, P. et al. 2013. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. British Journal of Cancer. 108: pp. 1052-1060. | |
| dc.identifier.uri | http://hdl.handle.net/20.500.11937/27277 | |
| dc.publisher | Nature Publishing Group | |
| dc.title | Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer | |
| dc.type | Journal Article | |
| dcterms.source.volume | 108 | |
| dcterms.source.startPage | 1052 | |
| dcterms.source.endPage | 1060 | |
| dcterms.source.issn | 00070920 | |
| dcterms.source.title | British Journal of Cancer | |
| curtin.accessStatus | Fulltext not available |